EYAL KEDAR
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- CANTON, NY
- NPI
- 1457599532
- Received
- $43,956 in 79 records, 2019 to 2025 ($22,200 general, $21,755 research)
- As principal investigator
- $1,857,798 of research payments to others in 184 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 4 | $1,458 |
| 2024 | General payment | 11 | $4,942 |
| 2024 | Research payment | 8 | $12,908 |
| 2023 | General payment | 8 | $6,283 |
| 2022 | General payment | 6 | $3,763 |
| 2022 | Research payment | 1 | $20 |
| 2021 | General payment | 5 | $5,114 |
| 2021 | Research payment | 3 | $1,103 |
| 2020 | General payment | 2 | $30 |
| 2020 | Research payment | 3 | $6,982 |
| 2019 | General payment | 27 | $607 |
| 2019 | Research payment | 1 | $740 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| GlaxoSmithKline, LLC. | 30 | $27,058 | 2019–2025 |
| Eli Lilly and Company | 10 | $13,653 | 2019–2024 |
| AstraZeneca UK Limited | 2 | $1,875 | 2023–2024 |
| Janssen Biotech, Inc. | 8 | $624 | 2019–2025 |
| AstraZeneca Pharmaceuticals LP | 4 | $233 | 2024 |
| ABBVIE INC. | 6 | $187 | 2019 |
| Novartis Pharmaceuticals Corporation | 2 | $143 | 2023–2025 |
| PFIZER INC. | 12 | $72 | 2019–2021 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $41 | 2019 |
| Amgen Inc. | 1 | $25 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 | 2019 |
| Alexion Pharmaceuticals, Inc. | 1 | $13 | 2019 |
| Genentech USA, Inc. | 1 | $10 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 16 | $21,755 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $18,750 |
| Consulting Fee | 1 | $1,860 |
| Food and Beverage | 34 | $842 |
| Education | 11 | $597 |
| Travel and Lodging | 1 | $150 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-10-22 | Janssen Biotech, Inc. | $77 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-19 | GlaxoSmithKline, LLC. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-07-31 | Novartis Pharmaceuticals Corporation | $80 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-02 | GlaxoSmithKline, LLC. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2024-12-04 | Janssen Biotech, Inc. | $68 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-11-26 | Eli Lilly and Company | $4,692 | Research payment | Cash or cash equivalent | TALTZ Drug, Immunology | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2024 |
| 2024-11-15 | AstraZeneca Pharmaceuticals LP | $150 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-11-15 | AstraZeneca Pharmaceuticals LP | $67 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-10-18 | AstraZeneca UK Limited | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-18 | GlaxoSmithKline, LLC. | $975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2024 | |
| 2024-08-21 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-08-20 | GlaxoSmithKline, LLC. | $237 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-08-16 | Eli Lilly and Company | $114 | Research payment | In-kind items and services | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2024 | |
| 2024-07-09 | GlaxoSmithKline, LLC. | $7,314 | Research payment | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-07-09 | GlaxoSmithKline, LLC. | $357 | Research payment | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-07-09 | GlaxoSmithKline, LLC. | $75 | Research payment | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-07-09 | GlaxoSmithKline, LLC. | $59 | Research payment | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-07-09 | GlaxoSmithKline, LLC. | $57 | Research payment | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-06-27 | Janssen Biotech, Inc. | $74 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2024 | |
| 2024-05-10 | GlaxoSmithKline, LLC. | $975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-02-08 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2024 | |
| 2024-02-08 | AstraZeneca Pharmaceuticals LP | $0 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2024 | |
| 2024-01-18 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2023-10-04 | GlaxoSmithKline, LLC. | $975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-08-10 | Janssen Biotech, Inc. | $79 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2023 | |
| 2023-07-21 | Novartis Pharmaceuticals Corporation | $63 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2023 | |
| 2023-06-21 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2023 | |
| 2023-05-16 | Janssen Biotech, Inc. | $55 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2023 | |
| 2023-05-05 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2023 | |
| 2023-04-25 | AstraZeneca UK Limited | $1,860 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-03-15 | GlaxoSmithKline, LLC. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2023 | |
| 2022-12-23 | GlaxoSmithKline, LLC. | $975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2022 | |
| 2022-10-07 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2022 | |
| 2022-09-15 | Janssen Biotech, Inc. | $91 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2022 | |
| 2022-05-25 | Janssen Biotech, Inc. | $89 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2022 | |
| 2022-04-08 | Eli Lilly and Company | $20 | Research payment | In-kind items and services | A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH | 2022 | |
| 2022-03-29 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2022 | |
| 2022-02-16 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2022 | |
| 2021-12-20 | GlaxoSmithKline, LLC. | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2021 | |
| 2021-12-07 | GlaxoSmithKline, LLC. | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2021 | |
| 2021-09-21 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2021 | |
| 2021-07-28 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2021 | |
| 2021-07-21 | GlaxoSmithKline, LLC. | $2,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | 2021 | |
| 2021-01-11 | Eli Lilly and Company | $826 | Research payment | In-kind items and services | A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH | 2021 | |
| 2021-01-11 | Eli Lilly and Company | $260 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2021 | |
| 2021-01-11 | Eli Lilly and Company | $17 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2021 | |
| 2020-12-08 | Eli Lilly and Company | $681 | Research payment | In-kind items and services | A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH | 2020 | |
| 2020-09-08 | Eli Lilly and Company | $826 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2020 | |
| 2020-01-28 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | NUCALA Biological, RESPIRATORY | 2020 | |
| 2020-01-23 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2020 | |
| 2020-01-09 | Eli Lilly and Company | $5,474 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2020 | |
| 2019-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $41 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2019 | |
| 2019-11-10 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | Rinvoq Biological, Immunology | 2019 | |
| 2019-11-09 | Janssen Biotech, Inc. | $86 | Food and Beverage | In-kind items and services | SIMPONI ARIA Biological, Immunology | 2019 | |
| 2019-11-08 | Eli Lilly and Company | $740 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2019 | |
| 2019-10-30 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-10-17 | GlaxoSmithKline, LLC. | $120 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2019 | |
| 2019-10-04 | Genentech USA, Inc. | $10 | Food and Beverage | In-kind items and services | Rituxan Biological, BioOncology/Immunology | 2019 | |
| 2019-09-10 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2019 | |
| 2019-09-05 | ABBVIE INC. | $14 | Education | In-kind items and services | Rinvoq Biological, Immunology | 2019 | |
| 2019-09-05 | ABBVIE INC. | $14 | Education | In-kind items and services | Rinvoq Biological, Immunology | 2019 | |
| 2019-09-05 | ABBVIE INC. | $14 | Education | In-kind items and services | Rinvoq Biological, Immunology | 2019 | |
| 2019-09-05 | ABBVIE INC. | $14 | Education | In-kind items and services | Rinvoq Biological, Immunology | 2019 | |
| 2019-09-05 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-07-25 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-07-25 | PFIZER INC. | $1 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-06-26 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2019 | |
| 2019-05-30 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-05-16 | ABBVIE INC. | $112 | Food and Beverage | In-kind items and services | Humira Biological, Immunology | 2019 | |
| 2019-05-07 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2019 | |
| 2019-03-22 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-03-08 | Alexion Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | Strensiq Drug, Endocrinology | 2019 | |
| 2019-03-06 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-03-01 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | Enbrel Biological, Inflammation | 2019 | |
| 2019-02-15 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-02-07 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-01-16 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 | |
| 2019-01-11 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2019 | |
| 2019-01-04 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-04 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $5,400 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-11-17 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $1,485 | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian | 2025 |
| 2025-11-05 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $10,179 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-10-07 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $43 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-10-02 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $314 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-09-11 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $4,937 | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa | 2025 |
| 2025-07-02 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $4,432 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-06-10 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $500 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-06-05 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $14 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-06-03 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $500 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2025 |
| 2025-05-30 | UCB SA | ST LAWRENCE HEALTH SYSTEM | $1,850 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2025 |
| 2025-05-27 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $275 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-05-16 | AstraZeneca Pharmaceuticals LP | SAINT LAWRENCE HEALTH SYSTEM | $20,934 | A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an | 2025 |
| 2025-05-07 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $2,416 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-05-01 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $3,646 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-04-28 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $405 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | 2025 |
| 2025-04-24 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $45 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-04-03 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $2,285 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-03-19 | AstraZeneca UK Limited | SAINT LAWRENCE HEALTH SYSTEM | $1,610 | A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneou | 2025 |
| 2025-03-07 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $4,519 | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit | 2025 |
| 2025-02-25 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $3,525 | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and | 2025 |
| 2025-02-25 | Eli Lilly and Company | ST LAWRENCE HEALTH SYSTEM INC | $16,551 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2025 |
| 2025-02-06 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $2,328 | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit | 2025 |
| 2025-01-28 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $31,711 | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa | 2025 |
| 2025-01-14 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $8,769 | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian | 2025 |
| 2024-12-30 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $5,400 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2024 |
| 2024-12-16 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $810 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-12-05 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $9,110 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $250 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $2,088 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $675 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | 2024 |
| 2024-11-20 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $10,000 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | 2024 |
| 2024-10-28 | UCB SA | ST LAWRENCE HEALTH SYSTEM | $4,350 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2024 |
| 2024-10-03 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $50 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2024 |
| 2024-10-03 | UCB SA | ST LAWRENCE HEALTH SYSTEM | $135 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2024 |
| 2024-09-25 | Eli Lilly and Company | ST LAWRENCE HEALTH SYSTEM INC | $1,935 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2024 |
| 2024-09-04 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $5,776 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2024 |
| 2024-08-27 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $675 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2024 |
| 2024-05-09 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $11,650 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2024 |
| 2024-04-08 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $7,428 | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa | 2024 |
| 2024-03-28 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM | $6,500 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2024 |
| 2024-02-27 | AstraZeneca Pharmaceuticals LP | SAINT LAWRENCE HEALTH SYSTEM | $2,841 | A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an | 2024 |
| 2024-02-09 | UCB SA | ST. LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS | $567 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2024 |
| 2024-02-07 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $6,000 | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab t | 2024 |
| 2024-01-24 | AstraZeneca UK Limited | SAINT LAWRENCE HEALTH SYSTEM | $3,045 | A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneou | 2024 |
| 2024-01-12 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM | $920 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2024 |
| 2024-01-09 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $45,912 | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian | 2024 |
| 2024-01-02 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $128,986 | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and | 2024 |
| 2024-01-02 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM | $538 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2024 |
| 2023-12-31 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM | $73 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2023 |
| 2023-11-29 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $6,500 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2023 |
| 2023-11-29 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $1,923 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2023 |
| 2023-11-29 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $675 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2023 |
| 2023-11-29 | GlaxoSmithKline, LLC. | ST LAWRENCE HEALTH SYSTEM INC | $2,500 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2023 |
| 2023-10-02 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM | $3,805 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2023 |
| 2023-10-02 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM | $10,969 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2023 |
| 2023-09-06 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $38,827 | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and | 2023 |
| 2023-08-25 | UCB SA | ST LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS | $567 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2023 |
| 2023-07-17 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $919 | A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis | 2023 |
| 2023-06-14 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY | $5,689 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2023 |
| 2023-06-01 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY | $6,061 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2023 |
| 2023-05-25 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $30,211 | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian | 2023 |
| 2023-05-03 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $4,416 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2023 |
| 2023-03-30 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $198 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2023 |
| 2023-03-24 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY | $12,282 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2023 |
| 2023-03-08 | AstraZeneca Pharmaceuticals LP | SAINT LAWRENCE HEALTH SYSTEM | $49,127 | A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an | 2023 |
| 2023-03-07 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $462 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2023 |
| 2023-02-25 | PFIZER INC. | ST LAWRENCE HEALTH SYSTEM | $598 | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED MULTICENTER DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PR | 2023 |
| 2023-02-16 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY | $15,723 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2023 |
| 2023-02-02 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $198 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2023 |
| 2023-01-25 | AstraZeneca UK Limited | SAINT LAWRENCE HEALTH SYSTEM | $2,015 | A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneou | 2023 |
| 2023-01-15 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $18 | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab t | 2023 |
| 2023-01-15 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $1,084 | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian | 2023 |
| 2023-01-11 | UCB SA | ST LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS | $14,648 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2023 |
| 2023-01-06 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $3,062 | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab t | 2023 |
| 2023-01-05 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $66 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2023 |
| 2023-01-04 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $194,138 | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and | 2023 |
| 2023-01-03 | Novartis Pharmaceuticals Corporation | SAINT LAWRENCE HEALTH RHEUMATOLOGY | $100,914 | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and | 2023 |
| 2022-12-31 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM | $440 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 |
| 2022-12-06 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $4,200 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 |
| 2022-11-03 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $275 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 |
| 2022-11-03 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $621 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 |
| 2022-09-23 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $66 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History o | 2022 |
| 2022-09-15 | Novartis Pharmaceuticals Corporation | ST LAWRENCE HEALTH SYSTEM CLINICAL RESEARCH | $12,652 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 3-ARM MULTICENTER PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF IAN | 2022 |
| 2022-09-05 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY | $22,885 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2022 |
| 2022-08-11 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $1,875 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi | 2022 |
| 2022-08-10 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $4,700 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi | 2022 |
| 2022-08-10 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $540 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi | 2022 |
| 2022-08-04 | F. Hoffmann-La Roche AG | ST LAWRENCE HEALTH SYSTEM INC | $2,200 | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2022 |
| 2022-08-04 | F. Hoffmann-La Roche AG | ST LAWRENCE HEALTH SYSTEM INC | $500 | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2022 |
| 2022-08-04 | F. Hoffmann-La Roche AG | ST LAWRENCE HEALTH SYSTEM INC | $1,000 | TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS | 2022 |
| 2022-06-09 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $2,750 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 |
| 2022-06-01 | Novartis Pharmaceuticals Corporation | ST LAWRENCE HEALTH SYSTEM ATTN CLINICAL RESEARCH | $132,060 | AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED SECUKINUMAB STUDY AND | 2022 |
| 2022-04-22 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $3,700 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History o | 2022 |
| 2022-04-20 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $590 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History o | 2022 |
| 2022-04-20 | ABBVIE INC. | ST LAWRENCE HEALTH SYSTEM INC | $14,300 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi | 2022 |
| 2022-04-14 | UCB SA | SAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY | $28,390 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2022 |
| 2022-03-11 | Eli Lilly and Company | ST LAWRENCE HEALTH SYSTEM INC | $15,205 | A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH | 2022 |
| 2022-03-08 | Eli Lilly and Company | COVANCE-DALLAS | $20 | A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH | 2022 |
| 2022-02-28 | UCB SA | ST LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS | $291 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Canton, NY, county St. Lawrence County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Canton, NY | County St. Lawrence County, NY | State New York |
|---|---|---|---|
| Population B01003 | 7,167 | 107,226 | 19,852,366 |
| Population, 2020 census P1 | 7,155 | 108,505 | 20,201,249 |
| Median age B01002 | 21.9 | 39.3 | 39.8 |
| Under 18 B01001 | 8.8% | 19.9% | 20.5% |
| 65 and over B01001 | 13.0% | 18.8% | 17.9% |
| Households B11001 | 2,029 | 41,666 | 7,722,646 |
| Foreign born B05002 | 6.0% | 3.7% | 22.8% |
| Median household income B19013 | $62,054 | $62,850 | $85,974 |
| Median family income B19113 | $125,163 | $80,443 | $106,873 |
| Per capita income B19301 | $24,044 | $33,177 | $50,712 |
| Poverty rate B17001 | 19.8% | 16.9% | 14.0% |
| Unemployment rate B23025 | 6.5% | 5.3% | 6.4% |
| Civilian labor force B23025 | 3,094 | 47,293 | 10,171,766 |
| Mean commute (minutes) B08013 | 13.1 | 21.0 | 32.6 |
| Bachelor's degree or higher B15003 | 53.9% | 25.3% | 40.2% |
| Housing units B25001 | 2,153 | 51,970 | 8,585,241 |
| Owner-occupied B25003 | 46.2% | 71.9% | 54.3% |
| Renters B25003 | 53.8% | 28.1% | 45.7% |
| Median home value B25077 | $183,800 | $121,900 | $423,800 |
| Median gross rent B25064 | $796 | $818 | $1,621 |
| White, not Hispanic B03002 | 83.9% | 91.2% | 52.8% |
| Black B03002 | 5.6% | 1.9% | 13.4% |
| Hispanic or Latino B03002 | 4.5% | 2.5% | 19.8% |
| Asian B03002 | 2.3% | 1.1% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.4% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Canton, NY.
Comments